

Resource Summary Report

Generated by [kravitz2](#) on Jul 31, 2026

Genomics of Drug Sensitivity in Cancer

RRID:SCR_011956

Type: Tool

Proper Citation

Genomics of Drug Sensitivity in Cancer (RRID:SCR_011956)

Resource Information

URL: <http://www.cancerrxgene.org/>

Proper Citation: Genomics of Drug Sensitivity in Cancer (RRID:SCR_011956)

Description: A genomics database project is an academic research program to identify molecular features of cancers that predict response to anti-cancer drugs.

Abbreviations: Genomics of Drug Sensitivity in Cancer

Resource Type: data or information resource, database

Keywords: compound, gene, molecule, drug, FASEB list

Related Condition: Cancer

Funding: Wellcome Trust

Resource Name: Genomics of Drug Sensitivity in Cancer

Resource ID: SCR_011956

Alternate IDs: OMICS_01581

Record Creation Time: 20220129T080307+0000

Record Last Update: 20260729T044301+0000

Ratings and Alerts

No rating or validation information has been found for Genomics of Drug Sensitivity in Cancer.

No alerts have been found for Genomics of Drug Sensitivity in Cancer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1418 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Luan R, et al. (2026) Pan-cancer multi-omics reveals DCAF7 as an immune-modulating prognostic driver and Wnt/ β -catenin activator in hepatocellular carcinoma. Clinical and translational medicine, 16(1), e70572.

Wen Q, et al. (2026) Identification and Validation of the Prognostic Value of PTTG1-Related Genes in Hepatocellular Carcinoma by Mendelian Randomization and Single-Cell Transcriptome Analysis. Iranian journal of biotechnology, 24(1), e4221.

Luo M, et al. (2025) Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations. Cancer discovery, 15(3), 511.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. Cancer research communications, 5(2), 375.

Li B, et al. (2025) Single-cell RNA sequencing reveals TMEM71 as an immunomodulatory biomarker predicting immune checkpoint blockade response in breast cancer. Discover oncology, 16(1), 1256.

Zhao Y, et al. (2025) Lactylation prognostic signature identifies DHCR7 as a modulator of chemoresistance and immunotherapy efficacy in bladder cancer. Frontiers in immunology, 16, 1585727.

Jiang K, et al. (2025) SOX4 mediates cancer-associated fibroblasts related radioresistance in hepatocellular carcinoma. Cellular oncology (Dordrecht, Netherlands), 48(5), 1449.

Luo W, et al. (2025) SLPI as a dedifferentiation biomarker in BRAFV600E-mutant papillary thyroid cancer. Endocrine connections, 14(8).

Zhang X, et al. (2025) Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. European journal of medical research, 30(1), 704.

Chen Z, et al. (2025) Orchestrated desaturation reprogramming from stearyl-CoA desaturase to fatty acid desaturase 2 in cancer epithelial-mesenchymal transition and metastasis. Cancer communications (London, England), 45(3), 245.

Zhao X, et al. (2025) CXCL8 modulates M0 macrophage proliferation and polarization to influence tumor progression in cervical cancer. Scientific reports, 15(1), 790.

Wu Y, et al. (2025) Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma. *Scientific reports*, 15(1), 954.

Tan W, et al. (2025) Characterization of tumor prognosis and sensitive chemotherapy drugs based on cuproptosis-related gene signature in ovarian cancer. *BMC women's health*, 25(1), 37.

Yang YC, et al. (2025) GNE-317 Reverses MSN-Mediated Proneural-to-Mesenchymal Transition and Suppresses Chemoradiotherapy Resistance in Glioblastoma via PI3K/mTOR. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(12), e2412517.

Qiao Q, et al. (2025) Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma. *Apoptosis : an international journal on programmed cell death*, 30(5-6), 1482.

Codicè F, et al. (2025) The specification game: rethinking the evaluation of drug response prediction for precision oncology. *Journal of cheminformatics*, 17(1), 33.

Wu Y, et al. (2025) Spatial multi-omics analysis of tumor-stroma boundary cell features for predicting breast cancer progression and therapy response. *Frontiers in cell and developmental biology*, 13, 1570696.

Wang Y, et al. (2025) Role of arachidonic acid metabolism in osteosarcoma prognosis by integrating WGCNA and bioinformatics analysis. *BMC cancer*, 25(1), 445.

Wen K, et al. (2025) Development of a m6A- and ferroptosis-related LncRNA signature for forecasting prognosis and treatment response in cervical cancer. *BMC cancer*, 25(1), 580.

Li X, et al. (2025) An antibody-dependent cellular phagocytosis-related gene signature predicts survival and response to immunotherapy in stomach adenocarcinoma. *Medicine*, 104(14), e42079.